Using Signos mHealth Platform in Adults for Weight Management

Running, not enrolling · Not applicable

Conditions studied: Overweight and Obesity, Metabolic Syndrome, Weight Loss

In brief

Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. The investigators hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.

Key facts

Study ID

NCT06214221

Run by

Signos Inc

People needed

380

Starts

2024-01-02

Expected to finish

2026-04-30

Last updated by the study team

2024-10-08

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• To join our study, participant need to:
• Be at least 22 years old.
• Be overweight or obese, which we define as having a Body Mass Index (BMI) between 25 and 40.
• HbA1c test result should be below 6.5% at the start of the study.
• Have and know how to use a smartphone that's compatible with the Signos app.
• Be able to understand, speak, and read English well enough to participate fully in the study.

You may not qualify if…

• Participant can't join our study if participant has:
• Have Type 1 or Type 2 diabetes.
• Are already using a device to monitor glucose level.
• Have severe allergies to the sticky part of glucose monitors.
• Suffer from an eating disorder like anorexia or bulimia.
• Are currently taking certain medications for diabetes or weight loss.
• Have had or are planning to have weight loss surgery.
• Have major health issues like severe kidney disease, untreated thyroid problems, or skin conditions where the glucose monitor would be placed.
• Have been part of another clinical trial recently.

Where it is running

• Helios Clinical Research (Phoenix) — Phoenix, Arizona, United States
• Diablo Clinical Research — Walnut Creek, California, United States
• Segal Trials — North Miami, Florida, United States
• Helios Clinical Research — Houston, Texas, United States
• Seattle Clinical Research — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.